HC Wainwright Issues Optimistic Forecast for ANRO Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Alto Neuroscience to a loss of $0.67 from $0.72 and maintained a “Buy” rating with a $55 price target.
• Alto Neuroscience reported a smaller-than-expected quarterly loss of $0.65 per share, beating the $0.73 consensus estimate. Analysts overall rate the stock “Moderate Buy,” with a consensus price target of $37.25.
• Despite recent forecast improvements and strong institutional buying, the clinical-stage biotech is still expected to remain unprofitable, with consensus full-year EPS of negative $2.71 and continued clinical, regulatory, and cash-burn risks.

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - HC Wainwright increased their Q3 2026 earnings estimates for shares of Alto Neuroscience in a report released on Monday, August 17th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.67) per share for the quarter, up from their previous estimate of ($0.72). HC Wainwright currently has a "Buy" rating and a $55.00 price target on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Alto Neuroscience's Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.80) EPS, Q1 2027 earnings at ($0.93) EPS, Q2 2027 earnings at ($0.97) EPS, Q3 2027 earnings at ($1.00) EPS, Q4 2027 earnings at ($0.96) EPS, FY2027 earnings at ($3.87) EPS, FY2028 earnings at ($4.39) EPS, FY2029 earnings at ($3.25) EPS and FY2030 earnings at ($1.29) EPS.

A number of other research analysts have also commented on ANRO. Bank of America began coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a "buy" rating and a $35.00 price objective on the stock. Wedbush lifted their target price on Alto Neuroscience from $24.00 to $26.00 and gave the stock a "neutral" rating in a report on Thursday, August 13th. BTIG Research boosted their target price on shares of Alto Neuroscience from $28.00 to $37.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. Wall Street Zen upgraded shares of Alto Neuroscience from a "strong sell" rating to a "sell" rating in a research note on Saturday. Finally, Zacks Research lowered shares of Alto Neuroscience from a "hold" rating to a "strong sell" rating in a research report on Wednesday, July 22nd. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Alto Neuroscience currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.25.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $34.19 on Wednesday. The firm has a market cap of $1.20 billion, a P/E ratio of -14.13 and a beta of 1.06. The business's 50 day moving average is $26.54 and its 200-day moving average is $23.04. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 1-year low of $3.32 and a 1-year high of $34.54.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08.

Hedge Funds Weigh In On Alto Neuroscience

Several hedge funds and other institutional investors have recently made changes to their positions in ANRO. Commodore Capital LP acquired a new position in shares of Alto Neuroscience during the fourth quarter worth $32,453,000. Perceptive Advisors LLC boosted its holdings in shares of Alto Neuroscience by 1,048.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company's stock valued at $31,762,000 after acquiring an additional 1,629,027 shares in the last quarter. Vestal Point Capital LP boosted its holdings in shares of Alto Neuroscience by 161.6% during the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company's stock valued at $44,233,000 after acquiring an additional 1,535,000 shares in the last quarter. Spruce Street Capital LP grew its position in Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company's stock worth $29,116,000 after acquiring an additional 1,102,366 shares during the last quarter. Finally, Vivo Capital LLC bought a new stake in Alto Neuroscience during the 4th quarter worth $18,433,000.

More Alto Neuroscience News

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: HC Wainwright raised its price target for Alto Neuroscience from $50 to $55 and maintained a “Buy” rating. The new target implies substantial upside from the recently referenced $34.19 share price. Alto Neuroscience Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: The firm improved its EPS forecasts across multiple periods, including fiscal 2026 through fiscal 2030 and each quarter from the third quarter of 2026 through the fourth quarter of 2027. Although Alto remains expected to report losses, the revised estimates indicate smaller losses—for example, fiscal 2026 EPS improved to $(2.80) from $(2.98), fiscal 2027 to $(3.87) from $(4.39), and fiscal 2030 to $(1.29) from $(1.53). This suggests HC Wainwright sees a stronger path toward profitability and supports investor optimism.
• Neutral Sentiment: The revisions remain analyst-driven and do not represent realized earnings or a new clinical-trial result. Alto Neuroscience is still expected to post a loss, with consensus EPS at approximately $(2.71) for the current year, so future clinical, regulatory, and cash-burn developments remain important risks.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source